Mariper

Perindopril, the active ingredient in Mariper, is an ACE inhibitor presented as an oral tablet for oral use. It is employed to treat hypertension, heart failure and to improve outcomes after myocardial infarction in adult patients.

GNH USA supplies Mariper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mariper, an ACE inhibitor, acts on the renin‑angiotensin‑aldosterone system to manage cardiovascular conditions.

Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Heart failure: improves ventricular function and decreases hospitalisation rates. Post‑myocardial infarction: supports cardiac remodeling and lowers the chance of recurrent events.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue or general weakness. - Hypotension: noticeable drop in blood pressure. - Altered taste sensation.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension leading to syncope. - Acute renal impairment or failure. - Neutropenia or agranulocytosis. - Hepatic dysfunction with jaundice. - Anaphylactic reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

Monitor blood pressure: adjust dose to maintain target levels. Assess renal function: check serum creatinine and eGFR periodically. Avoid in pregnancy: contraindicated due to fetal toxicity. Caution with potassium‑sparing diuretics: risk of hyperkalaemia. Review electrolyte balance: especially potassium and sodium. Store at room temperature: keep in the original container, protect from moisture and light.

Perindopril may interact with several medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade increases renal risk. - Lithium: ACE inhibition can raise lithium levels, risking toxicity. - Potassium supplements or high‑potassium diet: may cause hyperkalaemia. - Dual ACE inhibitor/ARB therapy: excessive blood pressure lowering and renal effects. - NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides, loop): may enhance hypotensive response. - Beta‑blockers: additive blood pressure reduction. - Antihyperglycaemic agents: ACE inhibitors may potentiate hypoglycaemia. - Rifampin: induces metabolism, reducing perindopril levels. - CYP450 inhibitors (e.g., ketoconazole): may increase perindopril exposure.